Doripenem
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bacterial Infections and Mycoses
Conditions
Bacterial Infections and Mycoses, Appendicitis, Cholecystitis, Pancreatitis, Peritonitis
Trial Timeline
Mar 1, 2004 → Jan 1, 2006
NCT ID
NCT00210938About Doripenem
Doripenem is a phase 3 stage product being developed by Johnson & Johnson for Bacterial Infections and Mycoses. The current trial status is completed. This product is registered under clinical trial identifier NCT00210938. Target conditions include Bacterial Infections and Mycoses, Appendicitis, Cholecystitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00986102 | Approved | Completed |
| NCT00211016 | Phase 3 | Completed |
| NCT00211003 | Phase 3 | Completed |
| NCT00210990 | Phase 3 | Completed |
| NCT00210938 | Phase 3 | Completed |
| NCT00229060 | Phase 3 | Completed |
Competing Products
20 competing products in Bacterial Infections and Mycoses